Vanoxerine: Cellular mechanism of a new antiarrhythmic

Journal of Cardiovascular Electrophysiology

Volumn 21, Issue 3, 2010, Pages 301-310

  Lacerda, Antonio E ^a   Kuryshev, Yuri A ^a   Yan, Gan Xin ^b,c   Waldo, Albert L ^d   Brown, Arthur M ^a  

^a ChanTest Corporation   (United States)

^b LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiarrhythmic drug; Cardiac electrophysiology; GBR 12909; Patch clamp; Purkinje fiber action potential; Vanoxerine; Ventricular wedge

Indexed keywords

CALCIUM CHANNEL; POTASSIUM CHANNEL HERG; SODIUM CHANNEL; VANOXERINE; ANTIARRHYTHMIC AGENT; PIPERAZINE DERIVATIVE;

ACTION POTENTIAL; ANIMAL CELL; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CALCIUM CURRENT; CELL STRAIN HEK293; CHANNEL GATING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG PROTEIN BINDING; HEART REPOLARIZATION; HEART VENTRICLE WALL; HUMAN; HUMAN CELL; MICROELECTRODE; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; PURKINJE FIBER; QT INTERVAL; SODIUM CURRENT; WAVEFORM; ANIMAL; CELL LINE; DRUG EFFECTS; DRUG SCREENING; KIDNEY; METABOLISM;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; CELL LINE; DOGS; DRUG EVALUATION, PRECLINICAL; HUMANS; KIDNEY; PIPERAZINES;

EID: 77649099565     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/j.1540-8167.2009.01623.x     Document Type: Article

References (30)

1. Waldo AL : A perspective on antiarrhythmic drug therapy to treat atrial fibrillation: There remains an unmet need. Am Heart J 2006 151 : 771 778.
2. AFFIRM First Antiarrhythmic Drug Substudy Investigators : Maintenance of sinus rhythm in patients with atrial fibrillation: An AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 2003 42 : 20 29.
3. Nattel S : Drugs to promote sinus rhythm reversion and maintenance in atrial fibrillation-why amiodarone is better. Cardiovasc Drugs Ther 2003 17 : 5 6.
4. Manios EG, Mavrakis HE, Kanoupakis EM, Kallergis EM, Dermitzaki DN, Kambouraki DC, Vardas PE : Effects of amiodarone and diltiazem on persistent atrial fibrillation conversion and recurrence rates: A randomized controlled study. Cardiovasc Drugs Ther 2003 17 : 31 39.
5. Giros B, el Mestikawy S, Godinot N, Zheng K, Han H, Yang-Feng T, Caron MG : Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol Pharmacol 1992 42 : 383 390.
6. Preti A : Vanoxerine National Institute on Drug Abuse. Curr Opin Investig Drugs 2000 1 : 241 251.
7. + current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 1990 96 : 195 215.
8. Sogaard U, Michalow J, Butler B, Lund LA, Ingersen SH, Skrumsager BK, Rafaelsen OJ : A tolerance study of single and multiple dosing of the selective dopamine uptake inhibitor GBR 12909 in healthy subjects. Int Clin Psychopharmacol 1990 5 : 237 251.
9. Ingwersen SH, Snel S, Mant TG, Edwards D : Nonlinear multiple-dose pharmacokinetics of the dopamine reuptake inhibitor vanoxerine. J Pharm Sci 1993 82 : 1164 1166.
10. Ingwersen SH, Mant TG, Larsen JJ : Food intake increases the relative oral bioavailability of vanoxerine. Br J Clin Pharmacol 1993 35 : 308 310.
11. Brown AM, Rampe D : Drug-induced long QT syndrome: Is HERG the root of all evil? Pharmaceutical News 2000 7 : 15 20.
12. + channels. Physiol Rev 2005 85 : 33 47.
13. Matsumoto N, Khrestian C, Ryu K, Lacerda A, Brown A, Waldo AL : Vanoxerine, a new drug for terminating atrial fibrillation and flutter. J Cardiovasc Electrophysiol DOI :.
14. Lacerda A, Matsumoto N, Khrestian C, Ryu K, Yan G-X, Waldo A, Brown A : Effects of vanoxerine on cardiac ion channels. 7th Annual NIH SBIR/STTR Conference 2005 B-5.
15. Kuryshev YA, Wible BA, Gudz TI, Ramirez AN, Brown AM : KChAP/Kvbeta1.2 interactions and their effects on cardiac Kv channel expression. Am J Physiol Cell Physiol 2001 281 : C290 C299.
16. Kuryshev YA, Ficker E, Wang L, Hawryluk P, Dennis AT, Wible BA, Brown AM, Kang J, Chen XL, Sawamura K, Reynolds W, Rampe D : Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 2005 312 : 316 323.
17. Lacerda AE, Kuryshev YA, Chen Y, Renganathan M, Eng H, Danthi SJ, Kramer JW, Yang T, Brown AM : Alfuzosin delays cardiac repolarization by a novel mechanism. J Pharmacol Exp Ther 2008 324 : 427 433.
18. Kirsch GE, Trepakova ES, Brimecombe JC, Sidach SS, Erickson HD, Kochan MC, Shyjka LM, Lacerda AE, Brown AM : Variability in the measurement of hERG potassium channel inhibition: Effects of temperature and stimulus pattern. J Pharmacol Toxicol Methods 2004 50 : 93 101.
19. Yan GX, Shimizu W, Antzelevitch C : Characteristics and distribution of M cells in arterially perfused canine left ventricular wedge preparations. Circulation 1998 98 : 1921 1927.
20. Yamashita N, Kaku T, Uchino T, Isomoto S, Yoshimatsu H, Ono K : Short- and long-term amiodarone treatments regulate Cav3.2 low-voltage-activated T-type Ca2+ channel through distinct mechanisms. Mol Pharmacol 2006 69 : 1684 1691.
21. Cherstniakova SA, Bi D, Fuller DR, Mojsiak JZ, Collins JM, Cantilena LR : Metabolism of vanoxerine, 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3- phenylpropyl)piperazine, by human cytochrome P450 enzymes. Drug Metab Dispos 2001 29 : 1216 1220.
22. Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Nielsen T, Rasmussen SL, Stiell IG, Coutu B, Ip JH, Pritchett EL, Camm AJ : Vernakalant hydrochloride for rapid conversion of atrial fibrillation: A phase 3, randomized, placebo-controlled trial. Circulation 2008 117 : 1518 1525.
23. Pratt CM, Roy D, Juul-Moller S, Torp-Pedersen C, Toft E, Wyse DG, Nielsen T, Rasmussen SL : Efficacy and tolerance of RSD1235 in the treatment of atrial fibrillation or atrial flutter: Results of a phase III, randomized, placebo-controlled, multicenter trial. J Am Coll Cardiol 2006 47 : 10A (Abstract).
24. Laughlin JC, Kowey PR : Dronedarone: A new treatment for atrial fibrillation. J Cardiovasc Electrophysiol 2008 19 : 1220 1226.
25. Chevalier P, Durand-Dubief A, Burri H, Cucherat M, Kirkorian G, Touboul P : Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: A meta-analysis. J Am Coll Cardiol 2003 41 : 255 262.
26. Goldsmith P, Golder Z, Hunt J, Berghmans S, Jones D, Stables JP, Murphree L, Howden D, Newton PE, Richards FM : GBR12909 possesses anticonvulsant activity in Zebrafish and rodent models of generalized epilepsy but cardiac ion channel effects limit its clinical utility. Pharmacology 2007 79 : 250 258.
27. Waldo AL, Camm AJ, deRuyter H, Freidman PL, MacNeil DJ, Pitt B, Pratt CM, Rodda BE, Schwartz PJ : Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: Rationale, design, and methods (the SWORD trial). Am J Cardiol 1995 75 : 1023 1027.
28. Goldstein I, Topilsky M, Segev D, Isakov A, Heller I : Very early onset of acute amiodarone pulmonary toxicity presenting with hemoptysis. Chest 1997 111 : 1446 1447.
29. Pollak PT : Clinical organ toxicity of antiarrhythmic compounds: Ocular and pulmonary manifestations. Am J Cardiol 1999 84 : 37R 45R.
30. Cakulev I, Kyungmoo R, Celeen K, Lacerda AE, Brown AM, Waldo AL : Orally administered vanoxerine, a cardiac multichcannel blocker, terminates atrial flutter and prevents its reinducibility in the canine sterile pericarditis model. J Am Coll Cardiol 2007 49 : 38A.